Physician profile
John L Schoonmaker
NPI 1841231537
$2,578.83
in general payments reported to CMS, 2019-2025
33 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.88 · 2020: $180 · 2021: $412 · 2022: $275 · 2023: $401 · 2024: $746 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $423.84 | 2021-2024 | Vraylar |
| Novo Nordisk INC | $383.15 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $322.63 | 2019-2023 | Lifevest |
| Pfizer INC. | $140.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $137.82 | 2022-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $135.35 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $106.12 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Eisai INC. | $97.00 | 2020-2021 | |
| Allergan, INC. | $95.35 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.56 | 2022-2024 | Xifaxan |
| Abbott Laboratories | $44.67 | 2021-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $41.63 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $40.17 | 2019-2022 | |
| Corcept Therapeutics | $38.25 | 2021-2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $37.92 | 2025 | Austedo Xr |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.20 | 2024 | Tradjenta, Jardiance |
| Amgen INC. | $36.85 | 2023-2024 | Otezla, Repatha, Prolia |
| E.R. Squibb & Sons, L.L.C. | $35.91 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.64 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $34.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.60 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $29.37 | 2025 | Voquezna |
| Kyowa Kirin, INC. | $27.51 | 2025 | |
| Esperion Therapeutics, INC. | $25.81 | 2021 | |
| Hologic Sales and Service, LLC | $24.34 | 2024 | Thinprep 2000 Processor, Aptima |
| Edwards Lifesciences Corporation | $22.92 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $21.63 | 2021 | |
| Horizon Therapeutics Plc | $21.21 | 2020 | |
| Mylan Specialty L.P. | $20.99 | 2024 | Yupelri |
| Boston Scientific Corporation | $19.71 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $18.45 | 2024 | Zoryve |
| Sumitomo Pharma America, INC. | $16.08 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $14.17 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schoonmaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.